Screening and Genetics: Maine Coons, Ragdolls and the proBNP Test

If you own a Maine Coon, a Ragdoll, or simply a cat you love and want to look after properly, you have probably come across the idea that hypertrophic cardiomyopathy can be screened for. The trouble is that the advice online is a muddle of gene swabs, blood tests and heart scans, often presented as if they are interchangeable. They are not. Each answers a different question, and knowing which question you are actually asking is the difference between useful reassurance and false comfort. This article is the plain-language map of feline HCM screening: who should be looked at, with what, and how to read the result. If you want the disease itself explained first, what a thickened heart is and why cats hide it so completely, the feline HCM explainer is the place to start.

Why we screen for a heart that looks perfectly well

HCM is the most common heart disease in cats, and its defining cruelty is that it is usually silent. In a study of apparently healthy cats, roughly one in seven, about 15%, turned out to have echocardiographically detectable cardiomyopathy, and nearly all of it was HCM (Paige et al., 2009). A large UK study of cats in rehoming centres found much the same prevalence (Payne et al., 2015). So screening is not hunting for a rare problem. It is shining a light into a corner where, statistically, a meaningful minority of perfectly normal-seeming cats are carrying disease their owners cannot see.

It matters because the first outward sign of HCM is too often a catastrophe: sudden heart failure, or a clot lodging where the aorta divides and paralysing the back legs. That clot, arterial thromboembolism, is the emergency every HCM owner must be able to recognise in seconds, and it has its own article, saddle thrombus, because it deserves the space. Screening exists to find the at-risk heart before that day, so the risk can be managed on your terms rather than in a 2am rush.

The genetics: what a Maine Coon or Ragdoll gene test really tells you

Two breeds have a specific, well-characterised genetic story, and they are the ones most owners ask about. In Maine Coons, a mutation in the MYBPC3 gene (the A31P variant) is associated with HCM, and a different MYBPC3 mutation (the R820W variant) has been described in Ragdolls (Meurs et al., 2005; Meurs et al., 2007). A cheek-swab test for these variants is cheap, available by post, and genuinely useful to a breeder. But it comes with three honest limitations that the marketing rarely spells out.

First, a positive gene test is not a diagnosis. These mutations raise risk, they do not guarantee disease, and they certainly do not tell you whether your cat's heart is thickened today. A cat can carry the variant and have a structurally normal heart for years, or for life. The gene tells you about probability, not present-day anatomy.

Second, a negative gene test does not clear your cat of HCM. This is the single most misunderstood point in feline cardiology screening. The known mutations explain only a fraction of HCM cases, even within Maine Coons, and plenty of cats with classic HCM test negative for every variant we can currently look for. In other breeds, and in the ordinary domestic shorthair, there is usually no validated gene test at all. A clear swab is reassuring about those specific variants and nothing more. It is not a heart-health certificate.

Third, the disease is not confined to the famous breeds. HCM is common across the whole cat population, including moggies, which is exactly why a normal-looking, unpedigreed cat can still develop it. The breeds simply carry an added, partly-mappable layer of inherited risk on top of the baseline that every cat shares.

So where does a gene test earn its place? Squarely in breeding decisions, which we will come back to. For an individual pet cat whose owner wants to know about the heart beating in its chest right now, the gene test is the wrong tool. For that, you need to look at the heart itself, or at the chemical footprint of a heart under strain.

The NT-proBNP blood test: a useful nudge, not a verdict

When heart muscle is stretched or working under strain, it releases a marker called NT-proBNP into the blood. Measuring it has become a popular screening shortcut, and there is a SNAP-type point-of-care version that a practice can run from a small blood sample in minutes. It is appealing precisely because it is so much easier than a scan. The catch is that its accuracy depends heavily on which version is used and on which cats.

The quantitative laboratory version, where blood is sent away and an actual number comes back, separates occult cardiomyopathy from normal hearts reasonably well, with sensitivity around 86% and specificity around 91% in a multicentre study (Fox et al., 2011). The in-clinic SNAP-type test is much weaker as a blanket screen of apparently healthy cats: in general-practice use it identified only around 43% of affected cats, rising to roughly 71% when restricted to cats that already had a murmur (Lu et al., 2021). Read those numbers carefully, because they carry the whole point. A positive proBNP meaningfully raises suspicion and should prompt a scan. A negative in-clinic result does not reliably clear the heart, because it misses too many affected cats to be trusted as an all-clear.

That is the honest framing for proBNP: a useful nudge towards a scan, not a verdict in its own right. It is at its best as a triage tool, helping decide who most needs an echocardiogram when scanning every cat is not practical, and it is reasonable to discuss it with your vet in exactly that spirit. What it cannot do is tell you, on its own, that a cat's heart is healthy. The deeper mechanics of how each blood marker behaves live in the tests explained; here, the message is simply that proBNP points the way, it does not close the case.

When an echocardiogram is the answer

The only test that actually diagnoses or excludes HCM is an echocardiogram, an ultrasound scan of the heart performed by an experienced operator, ideally a cardiologist (Luis Fuentes et al., 2020; Fox et al., 2011). It is the one tool on the list that looks directly at the structure in question and measures how thick the heart wall really is. Everything else infers, estimates or flags. The echo sees.

This is why, for any cat where the question genuinely matters, a known at-risk breed, a cat with a gallop sound or an arrhythmia, or a breeding animal, the scan is the high-value step and the others are signposts towards it. It is also the part with real-world friction, and it would be dishonest to pretend otherwise. A good echo usually means a referral to a cardiologist or a visiting specialist, it costs more than a blood test, and access varies by where you live. The working with a cardiologist article walks through what that referral involves and how to get the most from it.

One nuance worth knowing, so a borderline result does not panic you. HCM is not always a clean yes or no on a single scan. A cat may sit in an equivocal range where the wall is at the upper limit of normal, and the modern approach is often to rescan after a period rather than to label the cat prematurely (Luis Fuentes et al., 2020). A "we should look again in a year" is not a fudge. It is good medicine, because catching genuine thickening as it develops is more reliable than forcing a verdict on day one.

Screening before breeding: the responsibility that genetics is really for

This is where gene testing and echocardiography come into their own together, and where the stakes are highest, because a breeding cat does not pass on a problem to one animal but potentially to a whole litter, generation after generation. Responsible feline breeding bodies have long recommended that cats of predisposed breeds be screened by echocardiography before breeding and at intervals afterwards, because a cat with a normal heart at one year can develop HCM later, while still producing kittens in the meantime. A single clear scan as a kitten is not enough to call a breeding cat HCM-free for life.

Gene testing and scanning work best as a pair here, not as substitutes. The swab identifies carriers of the known MYBPC3 variants and lets a breeder make informed pairing decisions, avoiding the doubling-up that produces the most severely affected kittens (Meurs et al., 2005; Meurs et al., 2007). The serial echo checks what each cat's heart is actually doing as it ages, catching the disease the gene test cannot see and the cases it would miss entirely. A breeder relying on the swab alone, and skipping the scans, is screening for only a sliver of the risk. If you are buying a pedigree kitten, this is the question to ask the breeder plainly: are the parents echo-screened, by whom, and how recently?

There is a second "before" worth a single mention here, because owners often find this article while worrying about an operation. An at-risk cat facing a non-urgent anaesthetic is a strong reason to screen the heart first, but that decision has its own logic and its own article, so rather than re-tread it I will simply point you to HCM and anaesthesia, which covers who needs checking before a routine op and why a stiff heart copes badly with the drugs and the drip.

What a positive screen means for an apparently well cat

Here is the worry that screening creates, and it deserves a straight answer: if a scan finds early HCM in a cat who seems perfectly fine, what now? It is tempting to assume that finding the disease means starting lifelong medication, and bracing for the worst. Neither is quite right.

On medication, the consensus is unusually blunt. No treatment, not the ACE inhibitors, not spironolactone, not the beta-blocker atenolol, has been shown to slow progression or improve survival in subclinical HCM (Luis Fuentes et al., 2020). So a diagnosis in a well cat is generally not a prescription. We do not medicate a quiet, mild HCM heart in the hope of holding it back, because the evidence says it does not work. What a diagnosis does change is the plan: it sets the right recheck rhythm with your vet, it informs whether and when clot-prevention medication becomes worthwhile if the heart enlarges (the FATCAT evidence behind that decision is covered in preventing clots with clopidogrel), and it makes the next anaesthetic a cardiac-aware one rather than a routine one.

On prognosis, honesty cuts both ways. Many cats with mild HCM live for years with a good quality of life and may never progress to heart failure at all, and a diagnosis is emphatically not a death sentence. Equally, it is real, and it can advance, which is why monitoring matters. The single most valuable thing you can do at home, whether your cat has a confirmed diagnosis or simply sits in a watchful at-risk category, is keep an eye on the resting breathing rate while they sleep, because a sustained climb is the earliest at-home warning that fluid may be gathering. The resting respiratory rate guide explains exactly how to count it, and the breathing-rate tracker turns it into a quiet nightly habit that takes thirty seconds.

So a positive screen, read properly, is not bad news arriving early. It is information arriving early, which is the only kind worth having with a disease this quiet. It moves you from hoping your cat's heart is fine to knowing what it is doing and what to watch for. If your cat has been diagnosed and you are wondering what daily life looks like from here, the recheck cadence, the stress reduction, the small adjustments that add up, living with feline HCM picks up exactly where this leaves off.